Acurx announces publication of results from ibezapolstat study

Acurx (ACXP) Pharmaceuticals announced the publication of results from its scientific collaboration with Leiden University Medical Center, or LUMC, demonstrating structural biology research that reveals for the first time a DNA pol IIIC inhibitor, ibezapolstat, bound to its target. The publication is entitled: A unique inhibitor conformation selectively targets the DNA polymerase PolC of Gram-positive priority pathogens. The senior author is Wiep Klaas Smits, Associate Professor and Principal Investigator for Pol C Inhibitors, Leiden University Medical Center, Netherlands. According to Smits: “Results of this work provide mechanistic insights into ibezapolstat’s mode-of-action and a structural explanation for its selective antibacterial spectrum”. He added: “Advancement of small-molecule PolC inhibitors, a new-to-nature class of compounds, will be facilitated by these new insights into the structural determinants for inhibition laying the foundation for the rational development of an innovative class of antimicrobials against Gram-positive priority pathogens.”